October 5, 2018
Novo Nordisk is planning staff reductions of approximately 250 employees in the US as part of a reorganization resulting from an assessment of resource needs against its business priorities. Last month, the company announced staff reductions of 400 employees in research and development roles in China and Denmark.  Read More
Ian Read, CEO and Chairman, Pfizer will step down as CEO, effective January 1, 2019, with Albert Bourla, the company’s current Chief Operating Officer (COO), assuming the role of CEO. Read will transition into a new role as Executive Chairman of Pfizer’s Board of Directors. Read More
Following a court ruling, Fresenius, a specialty and generic pharmaceuticals company, has legally terminated its $4.75-billion merger with Akorn, a Lake Forest, Illinois-headquartered specialty generic pharmaceutical company. In April, Fresenius decided to terminate the merger agreement with Akorn due to Fresenius' assertion of Akorn’s failure to fulfill several closing conditions, including issues relating to data management.  Read More
Sanofi has completed its previously announced divestment of its European generics business, Zentiva, to Advent International, a private-equity firm, for approximately EUR 1.9 billion ($2.2 billion). Zentiva has manufacturing facilities in Prague and Bucharest, Romania, which produce and distribute more than 350 million packs each year. Read More
Novo Nordisk plans to establish a manufacturing site in Fremont, California to develop and produce stem cell-based therapies. The company has signed a long-term lease on a GMP facility, previously operated by Asterias Biotherapeutics, a biopharmaceutical company. Read More
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million in milestone payments). Tusk has developed an antibody with a mode of action aimed at depleting regulatory T-cells, which suppress immune responses, including those against cancer cells. Read More
Merck & Co. and Dragonfly Therapeutics, a company specializing in cancer immunotherapies, have partnered to discover, develop, and commercialize immunotherapies for patients with solid tumor cancers in a deal worth up to $695 million.  Read More
Dr. Reddy’s Laboratories, a Hyderabad, India-headquartered pharmaceutical company, has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a pharmaceutical company headquartered in Abu Dhabi, United Arab Emirates.  Read More
The European Medicines Agency (EMA) has revised the number of centrally authorized medicines (CAPs) for which there are concerns of supply disruptions due to the UK’s exit from the European Union (EU) (i.e., Brexit) from 108 to 39. In January, the EMA reported 108 medicines to be at risk following a survey of marketing authorization holders. Read More
A roundup of the latest expansions and investments from suppliers, CDMOs and CMOs, featuring news from Catalent Pharma Solutions, Brammer Bio, APC, and Dawtyler, as well as a CEO change at LabVantage. Read More
Top Industry News is published and distributed by the Drug, Chemical & Associated Technologies Association (DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit www.dcat.org .